The narrow path

Same author

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Leukemia·2020

Same author

Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?

Leukemia·2017

Same author

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Leukemia·2017

Same author

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

Bone marrow transplantation·2016

Same author

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Leukemia·2015

Same author

Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.

Neurology·2009

Same journal

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Videos

The narrow path

Related Concept Videos

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Related Experiment Videos

The narrow path

Related Concept Videos

Related Articles

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study.

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.